From the outsider’s perspective, FDA’s review and approval of Sandoz Inc.’s Zarxio (filgrastim-sndz) may have seemed like a relatively smooth and straightforward affair. Yet, there were a number of scientific challenges that the agency and sponsor had to work through before the first biosimilar could be approved.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?